Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Congenital heart block (CHB), also known as atrioventricular block, is a rare heart block disorder in which maternal antibodies attack the impulse-generating heart muscles of fetuses and newborns…
Hepatocellular carcinoma, the most common type of liver cancer, occurs as a result of chronic liver cirrhosis. It has a five-year survival rate of only 18%. First-line advanced hepatocellular…
The angiogenesis inhibitor Erbitux, in combination with platinum-based therapy and 5-fluorouracil (5-FU), was the standard treatment option for all squamous cell carcinoma of the head and neck (…
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disorder caused by inflammation and demyelination of the peripheral nerves characterized by weakness associated with loss of…
Bullous pemphigoid (BP) is the most common type of subepidermal autoimmune bullous diseases, which characteristically affects the elderly and is seen mainly in patients older than 60. The disease…
Inflammatory myositis (IM) is a heterogeneous group of autoimmune disorders characterized by immune-mediated muscle injury that results in muscle inflammation and skeletal muscle weakness…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs])…
Hemolytic disease of the fetus and newborn (HDFN), also known as alloimmune HDFN or erythroblastosis fetalis, is a rare red blood cell disorder in which maternal antibodies attack the red blood…
Clarivate Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
Clarivate Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key attention-deficit/hyperactivity disorder (ADHD) patient populations…
Clarivate Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
Clarivate Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of…